Invasive mucinous adenocarcinoma (IMA) of the lung represents 2-10% of all lung adenocarcinomas (LUAD) [1] [2] [3] . This histological subtype is considered as being one of the most malignant subtypes of LUAD, and is associated with a poor prognosis, probably due to frequent late-stage diagnosis [1] [2] [3] 
Introduction
unique treatment option at advanced stages, as to date no effective targeted therapy has shown its effectiveness.
The most commonly found genetic alterations in IMA are KRAS mutations, with a prevalence of 28-87% of cases [4] [5] [6] [7] [8] [9] [10] [11] [12] . Recently, recurrent CD74-NRG1 somatic gene fusions were discovered in IMA cases otherwise negative for known driver oncogenes (EGFR, KRAS, BRAF, ERBB2, ALK, ROS1) [13] . NRG1 (neuregulin 1) is usually not expressed in normal lung and in LUAD, but NRG1 fusions lead to NRG1 III-b3 isoform expression in IMA. By means of an extracellular EGF-like domain, NRG1 III-b3 binds the extracellular domain of ERBB3, leading to heterodimerization of ERBB3 with ERBB2. The resulting activation of the downstream PI3K-AKT and MAPK pathways promotes anchorageindependent growth of LUAD cell lines. As ERBB2-ERBB3 dimers and PI3K-AKT and MAPK pathways could be targetable, NRG1 fusions represent promising therapeutic targets [14] . Indeed, NRG1 fusion-mediated signaling could be effectively suppressed in vitro by tyrosine kinase inhibitors such as lapatinib and afatinib approved for clinical use.
CD74 is the most frequently found NRG1 fusion partner, but novel NRG1 partners have been described, such as SLC3A2-NRG1 and VAMP2-NRG1 in two independent cohorts of IMA and RBPMS-NRG1, WRN-NRG1, and SDC4-NRG1 in a cohort of LUAD and squamous lung carcinomas [11, 12, 15] .
NRG1 fusions could drive 7-27% of IMA and published data suggest that these oncogenic fusions essentially occur in nonsmoking women of Asian origin [11, 13, 16] . In this study, we sought to examine the prevalence and the clinical profile associated with NRG1 fusions in a French cohort of IMA patients.
Materials and Methods

Population studied
Twenty-five consecutive IMA patients surgically treated at Tenon Hospital (AP-HP), France, from 1991 to 2013, were retrieved from the Chest department database. The diagnosis was confirmed by a lung cancer pathologist (MA) and was based on the 2015 WHO classification of tumors of the lung [1] . Clinical findings at diagnosis and follow-up data were recorded. All patients signed a research informed consent form, permitting analysis of their biological samples. This study was approved by our hospital's ethics human research committee.
EGFR, KRAS, BRAF, and ERBB2 mutation analyses
For each formalin-fixed paraffin-embedded (FFPE) specimen, a 3-μm tissue section was stained with H&S and examined by light microscopy to determine the percentage of tumor cells. After DNA isolation (QIAamp DNA mini kit®, Qiagen, Courtaboeuf, France) from three 20 μm tissue sections, EGFR mutations G719S, T790M, and L858R (exons 18, 20, and 21, respectively), KRAS mutations G12S, G12R, G12C, G12A, G12V, and G13D (exon 2), and BRAF mutations V600E and V600K (exon 15) were detected with TaqMan®Assays (Custom TaqMan® SNP Genotyping Assays, Life Technologies SAS, Saint Aubin, France). EGFR exon 19 deletions, EGFR exon 20 insertions and ERBB2 exon 20 insertion were detected by sizing analysis. Sequencing data were then analyzed using SeqScape software.
ALK and ROS1 immunohistochemistry
Immunostainings of the ALK and ROS1 proteins were performed on 3-μm tissue sec tions on a Benchmark Ventana staining module (Ventana®, Roche Diagnostics, Meylan, France) using a primary monoclonal ALK antibody (Clone 5A4, Ab 17127; Abcam, Paris, France) diluted at 1:50 for 2 h at 37°C, or a primary monoclonal ROS1 antibody (Clone D4D6, #3287, Cell Signaling Technology®, Danvers, MA) at a dilution of 1:50 2 h at 20°C, as previously described. Positive external controls were performed, using a LUAD specimen that had been previously validated for ALK rearrangement by fluorescent in situ hybridization and the ROS1-rearranged cell line HCC78. The staining scores were assessed as follows: 0, no staining; 1+, faint cytoplasmic staining; 2+, moderate cytoplasmic staining; and 3+, intense granular cytoplasmic staining. The presence of 10% of cells stained with an intensity of ≥2 was considered as positive staining. Specimens with a positive staining score were tested for ALK or ROS1 rearrangement by FISH.
ALK, ROS1, and NRG1 break-apart FISH
FISH was performed on unstained 4-μm FFPE tumortissue sections using an ALK break-apart probe set (Vysis LSI ALK Dual Color®, Break Apart Rearrangement Probe; Abbott Molecular, Rungis, France) or a ZytoLight® SPEC ROS1 Dual Color Break Apart Probe (ZytoVision, Bremerhaven, Germany) and a paraffin-pretreated reagent kit (Vysis®, Abbott Molecular) according to the manufacturer's instructions. Tumor tissues were considered ALK-positive if >15% of the cells showed split orange and green signals and/or single orange signals or ROS1-positive if >15% of the cells showed split orange and green signals and/or single green signals.
As NRG1 fusions have been described in tumors without EGFR/KRAS/BRAF/HER2 mutations and ALK/ROS1 rearrangements, NRG1 break-apart FISH was performed only in pan wild-type samples.
An NRG1-specific fluorescent DNA probe was used kindly provided by ZytoVision (Zytolight SPEC NRG1 Dual Color Break Apart, ZytoVision, Bremerhaven, Germany). This probe contains green and orange-labeled polynucleotides, which target sequences mapping in 8p12 proximal to the NRG1 break point region. The 3' NRG1 probe is labeled with an orange spectrum fluorophore and the 5' NRG1 probe with a green spectrum fluorophore. The quality of each FISH experiment was categorized as good, moderate, or poor, according to the quality of the hybridization signals, and the presence of no to a very high fluorescent background noise, respectively. Tumor tissues were considered NRG1 FISHpositive when >15% of the nuclei harbored either a split pattern with 3′ and 5′ signals separated by a distance superior to the diameter of the largest signal, or isolated 3′ (orange) signals. This threshold was chosen by analogy with the threshold commonly used for other FISH assays for gene rearrangement detection in FFPE Nuclei were counterstained with DAPI/Vectashield® (Vektor Laboratories, Burlingame, CA) and were analyzed with a Leica CytoVision GSL10 FISH fluorescence capture system® (Leica, Nanterre, France) under a 63x oil immersion objective. Signals were enumerated with the CytoVision imaging system® (Leica). At least 100 nuclei were analyzed (mean = 126) for each tumor sample.
Results
Clinical and molecular findings for the 25 IMA patients are shown in Table 1 . All the driver oncogenes detected were mutually exclusive.
After analysis for EGFR, KRAS, BRAF, and ERBB2 mutations and ALK and ROS1 rearrangements, 11 samples remained wild-type for all driver oncogenes and were analyzed for NRG1 rearrangement by break-apart FISH. The FISH patterns found in our cohort are depicted in Figure 1 . The clinical findings and FISH quality and characteristics of each sample analyzed are shown in Table 2 .
One sample was NRG1 FISH-positive and 100% of the tumor nuclei analyzed were positive, harboring at least one isolated orange signal, together with at least 1 fusion signal (Fig. 2) . The frequency of each driver oncogene is shown in Figure 3 .
This NRG1-positive patient was a 61-year-old nonsmoking woman. sequelae of tuberculosis. Diagnosis was obtained by bronchoscopic cytology. Abdominal CT, brain magnetic resonance imaging (MRI), and positron emission tomography using 18F-fluorodeoxyglucose revealed no evidence of mediastinal node involvement or extra thoracic metastasis. Because of upper left lobe destruction, a left pneumonectomy was performed. Pathological analysis revealed an IMA which was TTF1 negative and CK7 and CK20 positive. The chest wall was invaded in an extent inferior to 1 centimeter and tumor cells were observed in one intralobar node. The tumor was classified as pT3N1M0. In view of the medical history of the patient, adjuvant chemotherapy was not administered and radiotherapy of the chest wall was performed. The disease relapsed 5 months after the surgery with appearance of numerous nodules in the remaining right lung on chest CT. The patient was enrolled in the IFCT-0504 clinical trial evaluating erlotinib or carboplatin/paclitaxel in advanced lepidic adenocarcinoma and was randomized in the erlotinib arm. After 4 weeks of erlotinib, the patient presented a respiratory failure secondary to a nondocumented right interstitial lung disease (ILD) which could be related to a disease progression or an erlotinib-induced ILD. She died after two weeks in intensive critical care unit.
Discussion
NRG1 rearrangements may be found by FISH in IMA wild-type for EGFR, KRAS, BRAF, ERBB2, ALK, and ROS1. Our series of 25 IMA showed one NRG1 FISH-positive case, corresponding to a prevalence of 4%. Previous works using high throughput transcriptome sequencing in frozen samples or anchored multiplex PCR and next-generation sequencing in FFPE samples estimated prevalence for NRG1 fusions in IMA of 7-27% [11] [12] [13] . The lower prevalence The NRG1 FISH-positive case was a Vietnamese nonsmoking woman, corresponding to the expected clinical profile reported in previous study (Table 3) [11, 13, 16] . It is remarkable that the only NRG1-positive case occurred in the sole patient of Asian ethnicity in our cohort. We speculate that NRG1 fusions might occur at a lower prevalence in IMA from Caucasian patients. Shim et al. reported the molecular analysis of two cohorts of IMA, one from Caucasian patients (n = 31) and one form Asian patients (n = 41). A trend for a lower prevalence of fusion in Caucasian was found but type of fusion according to ethnicity was not given.
The results of our study might indirectly suggest the scarcity of NRG1 fusions in IMA in Caucasian patients. However, there is a need of a dedicated study to answer the question of whether or not the prevalence of NRG1 fusion differs according to ethnicity. As NRG1 fusions could be targetable, NRG1 FISH detection should be considered in patients with IMA pan-negative for EGFR, KRAS, BRAF, ERBB2, ALK, and ROS1.
